RDY
Dr. Reddy's Laboratories Limited
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IN
$11.97
−0.50%Sep 2, 2026, 19:15 UTC
Aspen Pharmacare is pursuing the market for generic semaglutide, having obtained regulatory approval in Canada and awaiting registration in about 20 countries including Brazil and South Africa.
Source:Aug 4, 2026, 05:39 UTC
Dr. Reddy's Laboratories launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL single-dose vials, a generic equivalent of Bridion, in the United States.
Source:Jul 31, 2026, 14:45 UTC
Levi & Korsinsky announced an investigation into potential securities law violations by Dr. Reddy's Laboratories following a share price decline after the company disclosed a provision for out-of-spec semaglutide batches.
Source:Jul 31, 2026, 11:15 UTC
In July 2026, more than half of BSE 500 stocks underperformed the broader market, with 280 companies declining up to 22%, while benchmark indices ended the month higher.
Jul 30, 2026, 02:45 UTC
The USFDA completed a Pre-Approval Inspection and GMP inspection at Dr Reddy's Laboratories' FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, and issued a Form 483 with three observations.
Source:Jul 22, 2026, 12:28 UTC
Dr. Reddy's Laboratories plans to launch semaglutide in the market before November.
Source:Jul 22, 2026, 10:53 UTC
Dr Reddy's Laboratories reported its quarterly earnings on Wednesday, with profit falling short of expectations due to muted sales of a key generic oncology drug and pricing pressure in the U.S. market.
Jul 20, 2026, 02:22 UTC
Standard Chartered and Dr Reddy's Foundation signed an agreement to train and place 1,250 Persons with Disabilities by March 2028 across five Indian states.
Source:Jul 9, 2026, 03:48 UTC
Dr. Reddy's Laboratories announced that some batches of its semaglutide product do not meet specifications, is investigating the cause, and will delay commercial supply for a period of time.
Source:Jul 2, 2026, 12:00 UTC
Lupin has appointed Bijender Vats as senior vice president and head of human resources.
Source:Jun 29, 2026, 02:30 UTC
The USFDA completed a Pre-License Inspection at Dr Reddy's Laboratories' biologics manufacturing facility in Bachupally, Hyderabad.
Source:Jun 16, 2026, 12:00 UTC
Innoviva Specialty Therapeutics entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for XACDURO in select international markets.
Source:Jun 13, 2026, 10:22 UTC
Dr. Reddy's Laboratories Ltd. launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States.
Jun 7, 2026, 05:52 UTC
Dr. Reddy's Laboratories elevated Kunwar Khurana to Head of Sales and Marketing.
Source: